|
Session 85
Poster Abstracts
New Antiretroviral Agents and Approaches-Preclinical Studies
Monday, 1:30 - 3:30 pm
Poster Hall |
| 498 |
Amidate Prodrug of a Nucleotide Analog GS9148 Enhances the in vitro Intracellular Delivery of the Active Diphosphate Metabolite: Potential for Clinical Efficacy
Adrian Ray*, J Vela, R Mackman, L Zhang, H Hui, R Pakdaman, A Carey, M Wright, G Rhodes, and T Cihlar
Gilead Sci, Foster City, CA, US |
499
 |
Intracellular Metabolism of 2'-Deoxy-4'-C-Ethynyl-2-Fluoroadenosine, a Novel 4'-C-Ethynyl Nucleoside Analog Potent against Multidrug-resistant HIV-1 Variants
Hirotomo Nakata*1, Y Koh1, E Kodama2, G Yang3, S Kohgo4, H Hayakawa4, H Ohrui5, M Matsuoka2, Y C Chen3, and H Mitsuya1,6
1Kumamoto Univ Sch of Med, Japan; 2Inst for Virus Res, Kyoto Univ, Japan; 3Yale Univ, Sch of Med, New Haven, CT, US; 4Yamasa Corp, Chosi, Japan; 5Graduate Sch of Life Sci, Tohoku Univ, Sendai, Japan; and 6NCI, NIH, DHHS, Bethesda, MD, US |
500
|
Mutational Patterns Associated with Reduced and Increased Susceptibility to NcRTI in >6000 Clinical HIV-1 Isolates
Dirk Jochmans*1, H Van Marck1, M Van Ginderen1, I De Baere1, P Dehertogh1, A Peeters1, B Kesteleyn1, T Pattery2, P Mc Kenna2, and K Hertogs1
1Tibotec, Mechelen, Belgium and 2Virco, Mechelen, Belgium |
| 501 |
SPI-256, a Highly Potent HIV Protease Inhibitor with Broad Activity against MDR Strains
Sergei Gulnik*1, E Afonina1, M Eissenstat1, N Parkin2, A Japour1, and J Erickson1
1Sequoia Pharma, Gaithersburg, MD, US and 2Monogram Biosci, South San Francisco, CA, US |
| 502 |
Ritonavir Nanoparticles Inhibit Productive Replication of HIV-1ADA in MDM
Anuja Ghorpade*, K Rao, P Sahoo, S Sahoo, K Borgmann, R Persidsky, and V Labhasetwar
Univ of Nebraska Med Ctr, Omaha, US |
| 503 |
Determination of Resistance Profile of GRL-02031, a Novel Nonpeptidic Protease Inhibitor Containing a Cyclopentanyltetrahydrofuran Moiety
Yasuhiro Koh*1, H Nakata1, H Ogata-Aoki1, M Nakayama1, S Leschenko2, A Ghosh2, and H Mitsuya1,3
1Kumamoto Univ Sch of Med, Japan; 2Purdue Univ, West Lafayette, IN, US; and 3NCI, NIH, DHHS, Bethesda, MD, US |
| 504 |
Maraviroc Is a Slowly Reversible Antagonist at the Human CCR5 in a CRE Luciferase Reporter Gene Assay
S Pullen, H Sale, C Napier, Roy Mansfield*, and M Holbrook
Pfizer Global R&D, Sandwich, UK |
505
|
The Anti-CCR5 mAb004 Inhibits HIV-1 Replication Synergistically in Combination with Other Antiretroviral Agents but Does not Select for Resistance during in vitro Passage
Francoise Giguel*1, L Beebe2, T S Migone2, and D Kuritzkes1,3
1Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; 2Human Genome Sci, Rockville, MD, US; and 3Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US |
| 506 |
Resistance Profile of a Novel Broadly Neutralizing Anti-HIV Monoclonal Antibody, KD-247, that Has Favorable Synergism with Anti-CCR5 Inhibitors in vitro
Kazuhisa Yoshimura*1, J Shibata1, A Honda1, T Murakami2, H Mitsuya3, A Koito1, and S Matsushita1
1Ctr for AIDS Res, Kumamoto Univ, Japan; 2Chemo-Sero-Therapeutic Res Inst, Kumamoto, Japan; and 3Ctr for AIDS Res, Kumamoto Univ, Japan |
507
|
HIV-1 Entry Inhibitors Block Cell-to-Cell Infection in an in vitro Model of the Human Placental Barrier
Ahidjo Ayouba*, C Cannou, F Barré-Sinoussi, and E Menu
Inst Pasteur, Paris, France |
508
|
JTK-303/GS 9137, a Novel Small-molecule Inhibitor of HIV-1 Integrase: Anti-HIV Activity Profile and Pharmacokinetics in Animals
Yuji Matsuzaki*1, W Watanabe1, K Yamataka1, M Sato1, S Enya1, M Kano1, E Kodama2, M Matsuoka2, and S Ikeda1
1Japan Tobacco, Osaka and 2Inst for Virus Res, Kyoto Univ, Japan |
| 509 |
The First-in-Class Maturation Inhibitor, PA-457, Is a Potent Inhibitor of HIV-1 Drug-resistant Isolates and Acts Synergistically with Approved HIV Drugs in vitro
Nicole Kilgore*, M Reddick, M Zuiderhof, F Li, Y Abdul, C Matallana, D Zoumplis, A Castillo, K Salzwedel, and C Wild
Panacos Pharma, Gaithersburg, MD, US |
510
|
Indirubin-3’-monoxime, a Derivative of a Chinese Antileukemia Medicine, Inhibits P-TEFb Function and HIV-1 Replication: Potential Role of CDK9 Inhibition as a New Therapeutic Target
Alonso Heredia*, C Davis, D Bamba, N Le, M Gwarzo, M Sadowska, R Gallo, and R Redfield
Univ of Maryland, Baltimore, US |
| 511 |
Neurokinin-1 Receptor Antagonist Inhibits Drug-resistant HIV-1 Infection of Monocyte-derived Macrophages in vitro
Xu Wang*1,2, S Douglas1,2, J P Lai1,2, P Tebas2, J Lathey3, and W Z Ho1,2
1Children's Hosp of Philadelphia, PA, US; 2Univ of Pennsylvania, Philadelphia, US; and 3SeraCare BioSvcs, Gaithersburg, MD, US |
| 512 |
Interference of A-v Integrins Blocks HIV-1 Infection in Macrophages
B Bosch1, I Clotet-Codina1, J Blanco1, G Comma1, S Cedeño1, F Mitjans2, J Piulats2, M Bofill1, B Clotet1, and Jose A. Este*1
1Fndn irsiCaixa, Badalona, Spain and 2Merck Farma y Química, Barcelona, Spain |
513
|
A CD38-derived Peptide as a Potential Antiretroviral Agent Exploiting Cellular Mechanisms of Antiviral Defense
Andrea Savarino*1, T Bensi2, M Ferretti2, and U Dianzani2
1Univ Cattolica del Sacro Cuore, Rome, Italy and 2Univ of Eastern Piedmont, Novara, Italy |
| 514 |
siRNA-directed against HIV Co-receptor CCR5 Modulate IL-6 and IL-8 Secretion in a Sequence-specific Manner
Eduardo Pauls*, B Clotet, M Bofill, and J Este
Fndn irsiCaixa, Badalona, Spain |
|
